Keywords: eiffel, tech, makes, 3m, placing, accelerate, development
Eiffel Tech makes $3M placing to accelerate development
Article | 16 August 2004
Australian drug re-engineering company Eiffel Technologies has announcedthe placement of 36,363,637 fully-paid ordinary shares at a price of A$0.0825 per share, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
